Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Lipscombe
Date of last notice	25 January 2024

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder)	Bjouxz Pty Ltd <the fund="" loz="" superannuation=""></the>
Note: Provide details of the circumstances giving rise to the relevant interest.	
	Dr Lipscombe is beneficiary of the superannuation fund and sole director
	and shareholder of the trustee.
Date of change	21 November 2024
No. of securities held prior to change	Direct
	6,530,536 fully paid ordinary shares (Shares)
	Indirect 9,886,590 Shares

<sup>+</sup> See chapter 19 for defined terms.

Class	(a) Unquoted options exercisable at \$1.50 per option on or before 21 November 2027 (Tranche A Executive Options).
	(b) Unquoted options exercisable at \$2.50 per option on or before 21 November 2028 (Tranche B Executive Options)
	(c) Unquoted options exercisable at \$3.50 per option on or before 21 November 2028 (Tranche C Executive Options)
	The Executive Options have vesting periods as set out in Schedule 2 of the Notice of Annual General Meeting/Proxy Form dated 9 October 2024.
Number acquired	(a) 1,000,000 Tranche A Executive Options.
	(b) 800,000 Tranche B Executive Options
	(c) 800,000 Tranche C Executive Options.
Number disposed	Nil
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Non-cash consideration.  The primary purpose of the issue of the Executive Options is to provide a performance linked long-term incentive component in Dr Lipscombe's remuneration packages to motivate and reward his performance in his role as Managing Director.
	Estimated value of AUD 439,552 based on a Black Scholes valuation.
No. of securities held after change	Direct 6,530,536 Shares
	Indirect 9,886,590 Shares 1,000,000 Tranche A Executive Options. 800,000 Tranche B Executive Options 800,000 Tranche C Executive Options

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options as a long-term incentive following receipt of shareholder approval at the Annual General Meeting held on 8 November 2024.
---	--

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

## Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

<sup>+</sup> See chapter 19 for defined terms.

Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Williams
Date of last notice	20 September 2024

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
Date of change	21 November 2024
No. of securities held prior to change	Direct Nil.  Indirect Nil.
Class	<ul> <li>(a) Unquoted options exercisable at \$1.50 per option on or before 21 November 2027 (Director E Options).</li> <li>(b) Unquoted options exercisable at \$2.50 per option on or before 21 November 2028 (Director D Options)</li> </ul>
Number acquired	(a) 125,000 Director E Options. (b) 125,000 Director F Options.

<sup>+</sup> See chapter 19 for defined terms.

Number disposed	Nil
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Non-cash consideration. Issue of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees.
	Estimated value based on Black Scholes valuation:  • \$24,454 for Director E Options
	• \$21,813 for Director F Options.
No. of securities held after change	Direct 125,000 Director E Options. 125,000 Director F Options
	Indirect Nil
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of options following receipt of shareholder approval at the 2024 Annual General Meeting.

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

<sup>+</sup> See chapter 19 for defined terms.